Evolent Health Inc
NYSE:EVH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.71
34.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Evolent Health Inc
Wall Street
Price Targets
EVH Price Targets Summary
Evolent Health Inc
According to Wall Street analysts, the average 1-year price target for
EVH
is 25.65 USD
with a low forecast of 15.15 USD and a high forecast of 49.57 USD.
EVH Last Price Targets
Evolent Health Inc
The latest public price target was made on Nov 18, 2024 by
Mohan Naidu
from
Oppenheimer
,
who expects
EVH
stock to
rise by 145%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Mohan Naidu
Oppenheimer
|
28
USD
Upside 145% |
1 month ago
Nov 18, 2024
|
Evolent Health (EVH) PT Lowered to $28 at Oppenheimer
StreetInsider
|
|
Jeff Garro
Stephens
|
38
USD
Upside 233% |
2 months ago
Oct 17, 2024
|
Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens
TheFly
|
Jailendra Singh
Truist Financial
|
33
USD
Upside 189% |
4 months ago
Aug 9, 2024
|
Evolent Health upgraded to Buy from Hold at Truist
TheFly
|
Sean Dodge
RBC Capital
|
42
USD
Upside 268% |
6 months ago
Jun 5, 2024
|
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH)
StreetInsider
|
|
Jailendra Singh
Truist Financial
|
28
USD
Upside 145% |
7 months ago
May 14, 2024
|
Evolent Health (EVH) PT Lowered to $28 at Truist Securities
StreetInsider
|
Jessica Tassan
Piper Sandler
|
51
USD
Upside 347% |
8 months ago
Apr 17, 2024
|
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
StreetInsider
|
Richard Close
Canaccord Genuity
|
44
USD
Upside 286% |
8 months ago
Mar 28, 2024
|
Evolent Health (EVH) PT Lowered to $44 at Canaccord Genuity
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EVH's stock price target?
Price Target
25.65
USD
According to Wall Street analysts, the average 1-year price target for
EVH
is 25.65 USD
with a low forecast of 15.15 USD and a high forecast of 49.57 USD.
What is Evolent Health Inc's Revenue forecast?
Projected CAGR
20%
For the last 8 years the
compound annual growth rate for
Evolent Health Inc's revenue is
46%.
The projected
CAGR
for the next 4 years is
20%.
What is Evolent Health Inc's Operating Income forecast?
Projected CAGR
125%
The
compound annual growth rate
of Evolent Health Inc's operating income for the next 4 years is
125%.
You don't have any saved screeners yet
